NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other Events
Item 8.01. Other Events.
issued a press release titled “Data from Clinical Study of
NewLink Genetics IDO Pathway Inhibitor, Indoximod, to Be
Presented at the 22nd European Hematology Association Congress.”
incorporated herein by reference.
Press Release, dated May 18, 2017, entitled Data from
Clinical Study of NewLink Genetics
IDO Pathway Inhibitor, Indoximod, to Be Presented at
the 22nd European Hematology Association
About NewLink Genetics Corporation (NASDAQ:NLNK)
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer. NewLink Genetics Corporation (NASDAQ:NLNK) Recent Trading Information
NewLink Genetics Corporation (NASDAQ:NLNK) closed its last trading session down -0.25 at 16.10 with 610,253 shares trading hands.